• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

神经纤维瘤病2型(NF2)阻断间皮瘤中Snail介导的p53抑制作用。

NF2 blocks Snail-mediated p53 suppression in mesothelioma.

作者信息

Cho Jung-Hyun, Lee Su-Jin, Oh Ah-Young, Yoon Min-Ho, Woo Tae-Geun, Park Bum-Joon

机构信息

Department of Molecular Biology, Graduated School of System Biology, College of Natural Science, Pusan National University, Busan.

出版信息

Oncotarget. 2015 Apr 30;6(12):10073-85. doi: 10.18632/oncotarget.3543.

DOI:10.18632/oncotarget.3543
PMID:25823924
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4496341/
Abstract

Although asbestos causes malignant pleural mesothelioma (MPM), rising from lung mesothelium, the molecular mechanism has not been suggested until now. Extremely low mutation rate in classical tumor suppressor genes (such as p53 and pRb) and oncogenes (including Ras or myc) indicates that there would be MPM-specific carcinogenesis pathway. To address this, we treated silica to mimic mesothelioma carcinogenesis in mesothelioma and non-small cell lung cancer cell lines (NSCLC). Treatment of silica induced p-Erk and Snail through RKIP reduction. In addition, p53 and E-cadherin were decreased by silica-treatment. Elimination of Snail restored p53 expression. We found that NF2 (frequently deleted in MPM) inhibited Snail-mediated p53 suppression and was stabilized by RKIP. Importantly, GN25, an inhibitor of p53-Snail interaction, induced p53 and apoptosis. These results indicate that MPM can be induced by reduction of RKIP/NF2, which suppresses p53 through Snail. Thus, the p53-Snail binding inhibitor such as GN25 is a drug candidate for MPM.

摘要

尽管石棉会引发恶性胸膜间皮瘤(MPM),起源于肺间皮,但迄今为止其分子机制尚未明确。经典肿瘤抑制基因(如p53和pRb)和癌基因(包括Ras或myc)的极低突变率表明,MPM存在特定的致癌途径。为了探究这一点,我们用二氧化硅处理间皮瘤和非小细胞肺癌细胞系(NSCLC)以模拟间皮瘤致癌过程。二氧化硅处理通过降低RKIP诱导p-Erk和Snail。此外,二氧化硅处理使p53和E-钙黏蛋白减少。消除Snail可恢复p53表达。我们发现NF2(在MPM中经常缺失)抑制Snail介导的p53抑制,并被RKIP稳定。重要的是,p53-Snail相互作用抑制剂GN25可诱导p53和细胞凋亡。这些结果表明,RKIP/NF2的减少可诱导MPM,其通过Snail抑制p53。因此,诸如GN25这样的p53-Snail结合抑制剂是MPM的候选药物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/e80788c5f2f1/oncotarget-06-10073-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/9b59164e2866/oncotarget-06-10073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/1502a4a87112/oncotarget-06-10073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/e0d783f0b829/oncotarget-06-10073-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/0aee34880097/oncotarget-06-10073-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/1002deba9550/oncotarget-06-10073-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/0c03a2aa8024/oncotarget-06-10073-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/e80788c5f2f1/oncotarget-06-10073-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/9b59164e2866/oncotarget-06-10073-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/1502a4a87112/oncotarget-06-10073-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/e0d783f0b829/oncotarget-06-10073-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/0aee34880097/oncotarget-06-10073-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/1002deba9550/oncotarget-06-10073-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/0c03a2aa8024/oncotarget-06-10073-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b787/4496341/e80788c5f2f1/oncotarget-06-10073-g007.jpg

相似文献

1
NF2 blocks Snail-mediated p53 suppression in mesothelioma.神经纤维瘤病2型(NF2)阻断间皮瘤中Snail介导的p53抑制作用。
Oncotarget. 2015 Apr 30;6(12):10073-85. doi: 10.18632/oncotarget.3543.
2
Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.石棉相关肺癌和胸膜间皮瘤中的差异突变谱和相似的内含子 TP53 多态性。
Mutagenesis. 2013 May;28(3):323-31. doi: 10.1093/mutage/get008. Epub 2013 Feb 22.
3
Loss of NF2 Induces TGFβ Receptor 1-mediated Noncanonical and Oncogenic TGFβ Signaling: Implication of the Therapeutic Effect of TGFβ Receptor 1 Inhibitor on NF2 Syndrome.NF2 缺失诱导 TGFβ 受体 1 介导的非经典致癌 TGFβ 信号:TGFβ 受体 1 抑制剂对 NF2 综合征治疗效果的影响。
Mol Cancer Ther. 2018 Nov;17(11):2271-2284. doi: 10.1158/1535-7163.MCT-17-1210. Epub 2018 Aug 22.
4
Establishment and characterization of CRISPR/Cas9-mediated NF2 human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.建立并鉴定 CRISPR/Cas9 介导的 NF2 人间皮细胞系:对恶性胸膜间皮瘤中成纤维细胞生长因子受体 2 的分子研究。
Cancer Sci. 2019 Jan;110(1):180-193. doi: 10.1111/cas.13871. Epub 2018 Dec 14.
5
Mithramycin Depletes Specificity Protein 1 and Activates p53 to Mediate Senescence and Apoptosis of Malignant Pleural Mesothelioma Cells.光辉霉素消耗特异性蛋白1并激活p53以介导恶性胸膜间皮瘤细胞的衰老和凋亡。
Clin Cancer Res. 2016 Mar 1;22(5):1197-210. doi: 10.1158/1078-0432.CCR-14-3379. Epub 2015 Oct 12.
6
Targeting of the Hedgehog signal transduction pathway suppresses survival of malignant pleural mesothelioma cells in vitro.靶向 Hedgehog 信号转导通路抑制恶性胸膜间皮瘤细胞的体外存活。
J Thorac Cardiovasc Surg. 2014 Jan;147(1):508-16. doi: 10.1016/j.jtcvs.2013.08.035. Epub 2013 Oct 4.
7
Merlin deficiency predicts FAK inhibitor sensitivity: a synthetic lethal relationship.梅林缺失预测 FAK 抑制剂敏感性:一种合成致死关系。
Sci Transl Med. 2014 May 21;6(237):237ra68. doi: 10.1126/scitranslmed.3008639.
8
Co-occurring Mutations of Tumor Suppressor Genes, and , in Malignant Pleural Mesothelioma.恶性胸膜间皮瘤中肿瘤抑制基因 和 共存突变。
Clin Cancer Res. 2017 Jun 15;23(12):3191-3202. doi: 10.1158/1078-0432.CCR-16-1971. Epub 2016 Dec 21.
9
Combined Inhibition of NEDD8-Activating Enzyme and mTOR Suppresses Loss-Driven Tumorigenesis.NEDD8 激活酶和 mTOR 的联合抑制抑制了驱动损失的肿瘤发生。
Mol Cancer Ther. 2017 Aug;16(8):1693-1704. doi: 10.1158/1535-7163.MCT-16-0821. Epub 2017 May 3.
10
MicroRNA-215-5p Treatment Suppresses Mesothelioma Progression via the MDM2-p53-Signaling Axis.微小 RNA-215-5p 通过 MDM2-p53 信号轴抑制间皮瘤进展。
Mol Ther. 2019 Sep 4;27(9):1665-1680. doi: 10.1016/j.ymthe.2019.05.020. Epub 2019 Jun 4.

引用本文的文献

1
Therapeutic effect of novel drug candidate, PRG-N-01, on NF2 syndrome-related tumor.新型候选药物PRG-N-01对NF2综合征相关肿瘤的治疗效果。
Neuro Oncol. 2025 Jun 21;27(5):1241-1255. doi: 10.1093/neuonc/noae282.
2
NF2-Related Schwannomatosis (NF2): Molecular Insights and Therapeutic Avenues.NF2 相关神经鞘瘤病(NF2):分子见解与治疗途径。
Int J Mol Sci. 2024 Jun 14;25(12):6558. doi: 10.3390/ijms25126558.
3
Opposing Roles of Wild-type and Mutant p53 in the Process of Epithelial to Mesenchymal Transition.野生型和突变型p53在上皮-间质转化过程中的相反作用

本文引用的文献

1
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit.通过中断自分泌细胞因子回路抑制KRAS驱动的肿瘤发生。
Cancer Discov. 2014 Apr;4(4):452-65. doi: 10.1158/2159-8290.CD-13-0646. Epub 2014 Jan 20.
2
A new p53 target gene, RKIP, is essential for DNA damage-induced cellular senescence and suppression of ERK activation.一个新的 p53 靶基因 RKIP 对于 DNA 损伤诱导的细胞衰老和 ERK 激活的抑制是必需的。
Neoplasia. 2013 Jul;15(7):727-37. doi: 10.1593/neo.121862.
3
Molecular pathogenesis of malignant mesothelioma.
Front Mol Biosci. 2022 Jun 23;9:928399. doi: 10.3389/fmolb.2022.928399. eCollection 2022.
4
Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling.肺癌中 Raf 激酶抑制剂蛋白 (RKIP) 的现状:RTK 信号背后的作用。
Cells. 2019 May 10;8(5):442. doi: 10.3390/cells8050442.
5
Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.沉默蜗牛依赖性 RNA 剪接调控因子 ESRP1 驱动人肺上皮细胞恶性转化。
Cancer Res. 2018 Apr 15;78(8):1986-1999. doi: 10.1158/0008-5472.CAN-17-0315. Epub 2018 Feb 5.
6
Heterogeneous Contributing Factors in MPM Disease Development and Progression: Biological Advances and Clinical Implications.恶性胸膜间皮瘤发病和进展的异质影响因素:生物学进展及临床意义。
Int J Mol Sci. 2018 Jan 13;19(1):238. doi: 10.3390/ijms19010238.
7
Correction to: Leucine-Rich Repeat Kinase 2 (LRRK2) phosphorylates p53 and induces p21 expression.对《富含亮氨酸重复激酶2(LRRK2)磷酸化p53并诱导p21表达》的更正
Mol Brain. 2017 Oct 6;10(1):48. doi: 10.1186/s13041-017-0327-6.
8
Does rarity mean imparity? Biological characteristics of osteosarcoma cells originating from the spine.罕见是否意味着不同?源自脊柱的骨肉瘤细胞的生物学特征。
J Cancer Res Clin Oncol. 2017 Oct;143(10):1959-1969. doi: 10.1007/s00432-017-2448-9. Epub 2017 May 27.
9
Metformin produces growth inhibitory effects in combination with nutlin-3a on malignant mesothelioma through a cross-talk between mTOR and p53 pathways.二甲双胍与Nutlin-3a联合使用时,通过mTOR和p53信号通路之间的相互作用对恶性间皮瘤产生生长抑制作用。
BMC Cancer. 2017 May 2;17(1):309. doi: 10.1186/s12885-017-3300-y.
恶性间皮瘤的分子发病机制。
Carcinogenesis. 2013 Jul;34(7):1413-9. doi: 10.1093/carcin/bgt166. Epub 2013 May 14.
4
RKIP regulates MAP kinase signaling in cells with defective B-Raf activity.RKIP 调节 B-Raf 活性缺陷细胞中的 MAP 激酶信号转导。
Cell Signal. 2013 May;25(5):1156-65. doi: 10.1016/j.cellsig.2013.02.005. Epub 2013 Feb 14.
5
Tumours associated with BAP1 mutations.与 BAP1 突变相关的肿瘤。
Pathology. 2013 Feb;45(2):116-26. doi: 10.1097/PAT.0b013e32835d0efb.
6
Prognostic value of RKIP and p-ERK in gastric cancer.RKIP 和 p-ERK 在胃癌中的预后价值。
J Exp Clin Cancer Res. 2012 Mar 31;31(1):30. doi: 10.1186/1756-9966-31-30.
7
Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.凡德他尼在间皮瘤中作为一种有效的抗肿瘤药物的临床前出现:与培美曲塞和卡铂协同作用的分子机制。
Br J Cancer. 2011 Nov 8;105(10):1542-53. doi: 10.1038/bjc.2011.400. Epub 2011 Oct 4.
8
Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma.miRNA-34b/c 的表观遗传沉默在恶性胸膜间皮瘤的发病机制中发挥着重要作用。
Clin Cancer Res. 2011 Aug 1;17(15):4965-74. doi: 10.1158/1078-0432.CCR-10-3040. Epub 2011 Jun 14.
9
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma.恶性胸膜间皮瘤中,核去泛素化酶 BAP1 通常因体细胞突变和 3p21.1 缺失而失活。
Nat Genet. 2011 Jun 5;43(7):668-72. doi: 10.1038/ng.855.
10
Combined chemotherapy with cytotoxic and targeted compounds for the management of human malignant pleural mesothelioma.联合细胞毒和靶向化合物化疗治疗人类恶性胸膜间皮瘤。
Trends Pharmacol Sci. 2011 Aug;32(8):463-79. doi: 10.1016/j.tips.2011.03.011. Epub 2011 May 26.